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Abstract The novel synthetic analogues D-3-fluoro-wyo-inositol 
l,5-bisphosphate-4-phosphorothioate, [3F-Ins(l,5)P2-4PSl, D-3-
fluoro-znyo-inositol l,4-bisphosphate-5-phosphorothioate [3F-
Ins(l,4)P2-5PS], and D-3-fluoro-inyo-inositol l-phosphate-4,5-
bisphosphorothioate [3F-Ins(l)P-(4,5)PS2] were utilised to define 
the structure-activity relationships which could produce partial 
agonism at the Ca2+ mobilising «yo-inositol 1,4,5-trisphosphate 
[Ins(l,4,5)P3] receptor. Based on prior structure-activity data we 
hypothesised that the minimal structural requirements for 
Ins(l,4,5)P3 receptor partial agonism, were phosphorothioate 
substitution of the crucial vicinal 4,5-bisphosphate pair accom-
panied by another structural perturbation, such fluorination of 3-
position of the mjo-inositol ring. All the analogues fully 
displaced |3H]Ins(l,4,5)P3 from a single Ins(l,4,5)P3 binding 
site in pig cerebellar membranes [3F-Ins(l,5)P2-4PS (IC50 = 26 
nM), 3F-Ins(l,4)P2-5PS (IC50 = 80 nM) and 3F-Ins(l)P-
(4,5)PS2 (IC50 = 109 nM) cf. Ins(l,4,5)P3 (IC50 = 11 nM)]. In 
contrast, 3F-Ins(l,5)P2-4PS (IC50 = 424 nM) and 3F-Ins(l,4)P2-
5PS (IC50 = 3579 nM) were weak full agonists at the Ca
2+ 
mobilising Ins(l,4,5)P3 receptor of permeabilised SH-SY5Y 
neuroblastoma cells, being respectively 4- and 36-fold less potent 
than Ins(l,4,5)P3 (EC50 = 99 nM). While 3F-Ins(l)P-(4,5)PS2 
(EC50 = 11345 nM) was a partial agonist releasing only 
64.3 ±1.9% of the Ins(l,4,5)P3-sensitive intracellular Ca
2+ 
pools. 3F-Ins(l)P-(4,5)PS2 was unique among the Ins(l,4,5)P3 
receptor partial agonists so far identified in having a relatively 
high affinity for the Ins(l,4,5)P3 binding site, accompanied by a 
significant loss of intrinsic activity for Ca2+ mobilisation. This 
improved affinity was probably due to the retention of the 1-
position phosphate, which enhances interaction with the Ins-
(1,4,5)P3 receptor. 3F-Ins(l)P-(4,5)PS2 may be an important 
lead compound for the development of efficient Ins(l,4,5)P3 
receptor antagonists 
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fluoro-myo-inositol l,5-bisphosphate-4-phosphorothioate; 3F-
Ins(l,4)P2-5PS, D-3-fluoro-wrco-inositol l,4-bisphosphate-5-phospho-
rothioate; 3F-Ins(l)P-(4,5)PS2, D-3-fluoro-m^o-inositol 1-phosphate-
4,5-bisphosphorothioate; Ins(l,4,5)PsR, D-ra>>o-inositol 1,4,5-trisphos-
phate receptor; CLB, cytosolic like buffer; EC50, concentration 
producing 50% of maximal effect; IC50, concentration producing 
50% of maximal inhibition. 
1. Introduction 
D-wyo-Inositol 1,4,5-trisphosphate [Ins(l,4,5)P3] receptors 
are recognised as a homologous family of tetrameric ligand-
gated Ca2+ channels, which allow mobilisation of intracellular 
Ca2+ stores in response to activation of cell-surface receptors 
linked to Ins(l,4,5)P3 generation [1]. The interaction of 
Ins(l,4,5)P3 with its receptor is highly stereospecific, the vici-
nal 4,5-bisphosphate and 6-hydroxyl motif being the crucial 
structural features, and the 1-phosphate of lns(l,4,5)P3 fur-
ther contributing to receptor binding specificity (reviewed [2]). 
Partial or total phosphorothioate substitution of the phos-
phate groups appears to well tolerated, producing high affinity 
ligands which are resistant to metabolism catalysed by the 
specific enzymes Ins(l,4,5)P3-3-kinase and Ins(l,4,5)P3-5-
phosphatase [3-5]. Whilst Ins(l,4,5)PS3 has only a slightly 
lower affinity than Ins(l,4,5)P3 at binding sites characterised 
with [3H]Ins(l,4,5)P3, inositol l,4,5-[
35S(U)]trisphosphoro-
thioate was able to specifically label two specific binding site 
populations [6]. Thus, Ins(l,4,5)PS3 appears to exhibit a sub-
tly different interaction with the binding pocket of the 
Ins(l,4,5)P3R [Ins(l,4,5)P3R]. 
The 2,3,6-hydroxyl groups of Ins(l,4,5)P3 also contribute to 
the Ins(l,4,5)P3R interaction by either donating or accepting 
hydrogen bonds with the receptor, or alternatively via fixing 
the solution conformation of Ins(l,4,5)P3 by intramolecular 
hydrogen bonding to the neighbouring phosphates [7]. The 
6-OH group makes a significant contribution [8,9], whereas 
the axial 2-hydroxyl (OH) and equatorial 3-OH per se, do 
not appear to be as critical for Ins(l,4,5)P3R binding and 
Ca2+ release [9,10]. The Ins(l,4,5)P3R has a remarkable tol-
erance for electronic and steric modification of the 2-position 
of Ins(l,4,5)P3 for either axial or equatorial substituents, sug-
gesting that the 2-OH is not intimately associated with the 
receptor binding pocket (reviewed [11]). In contrast, inversion 
of the 3-OH [12,13] produces loss of activity, while increasing 
the steric bulk of the 3-position substituent of Ins(l,4,5)P3 
analogues correlates with progressively decreasing activity at 
the Ins(l,4,5)P3R [14]. Notably some modifications of the 
equatorial 3-position hydroxyl of Ins(l,4,5)P3 affect the intrin-
sic activity at the Ins(l,4,5)P3R. Indeed, the first partial ago-
nist identified at the Ins(l,4,5)P3R was the naturally occurring 
myo-inositol 1,3,4,6-tetrakisphosphate [Ins(l,3,4,6)P4] [11,15]; 
significantly Ins(l,3,4,6)P4 adopts a binding conformation 
which efficiently mimics Ins(l,4,5)P3 with the exception of 
presenting an axial (pseudo) 3-phosphate [7]. Additionally, 
recently two low intrinsic activity partial agonists; h-chiro-
inositol 2,3,5-trisphosphorothioate [L-cA-Ins(2,3,5)PS3], D-
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793(96)01540-2 
242 KA. Wilcox et allFEBS Letters 402 (1997) 241-245 
6-deoxy-myo-inositol 1,4,5-trisphosphorothioate [6-deoxy-
Ins(l,4,5)PS3] [16] and a high intrinsic activity partial agonist; 
scy/fo-inositol 1,2,4,5-tetrakisphosphorothioate [11] have been 
identified. Thus, al though Ins(l,4,5)PS3 itself was a full ago-
nist, replacement of the D-l,4,5-trisphosphate motif with 
phosphorothioates appears to assist in triggering a substantial 
loss of agonist efficacy, accompanied by a less significant loss 
of affinity. 
We have designed and synthesised three analogues; D-3-flu-
oro-rayo-inositol l ,5-bisphosphate-4-phosphorothioate [3F-
Ins(l,5)P2-4PS], D-3-fluoro-myo-inositol l ,4-bisphosphate-5-
phosphorothioate [3F-Ins(l,4)P2-5PS] and D-3-fluoro-w^o-
inositol l-phosphate-4,5-bisphosphorothioate [3F-Ins(l)P-
(4,5)PS2] (Fig. 1), to test whether phosphorothioate substitu-
tion at the crucial vicinal 4,5-bisphosphate motif, in combina-
tion with a further moderate structural perturbation, could 
trigger partial agonism. Here we present data to confirm 
our hypothesis that 4,5-bisphosphorothioate substitution and 
3-position fluorination of Ins(l,4,5)P3 can indeed produce 
partial agonism at the Ins(l ,4,5)P3R. 
2. Materials and methods 
2.1. Materials 
Most reagents used were as previously described [17]. Disodium 
ATP and EGTA were from Sigma (UK). All other reagents were of 
the highest purity available. Chemically synthesised Ins(l,4,5)P3 [18] 
as the hexapotassium salt, was obtained from Cell Signals Inc, Lex-
ington, Kentucky, USA. 45CaCl2 (approx. 1000 Ci/mmol, Amersham) 
and [3H]Ins(l,4,5)P3 (41 Ci/mmol, Amersham, UK) were used 
throughout. D-3-Fluoro-«yo-inositol 1,5-bisphosphate-4-phosphoro-
thioate [3F-Ins(l,5)P2-4PS], D-3-fluoro-raj>o-inositol 1,4-bisphos-
phate-5-phosphorothioate [3F-Ins(l,4)P2-5PS], and D-3-fluoro-myo-in-
ositol l-phosphate-4,5-bisphosphorothioate [3F-Ins(l)P-(4,5)PS2] were 
used as the tetraethylammonium salts; their full synthesis and a pre-
liminary report on the metabolic stability of 3F-Ins(l,4)P2-5PS and 
3F-Ins(l)P-(4,5)PS2 have been published elsewhere [19]. 
2.2. Cell culture 
SH-SY5Y human neuroblastoma cell monolayers (passage 70-90), 
initially a gift from Dr J.L. Biedler (Sloane-Kettering Institute, New 
York, USA) were subcultured and maintained, as described [17], ex-
cept that the culture media was serum supplemented with 10% (v/v) 
new-born calf serum and 1% foetal calf serum (Gibco, UK). Cell 
monolayers were harvested for experiments using a buffer consisting 
of 0.02% (w/v) EDTA-Na2 (537 uM), 0.9% (w/v) NaCl (154 mM) and 
HEPES(free acid) 10 mM, pH 7.2. These neuronally derived cells 
predominantly express the type 1 (cerebella) Ins(l,4,5)P3R [20,21], 
thus allowing direct comparison with the binding preparation of cer-
ebellar Ins(l,4,5)P3Rs [22]. 
2.3. Ins(l,4,5)P-t binding studies 
Preparation of 'P2' membranes from pig cerebellum and the 
[3H]Ins(l,4,5)P3 binding and displacement assays were performed as 
described [23]. After incubation for 30 min at 4°C bound and free 
[3H]Ins(l,4,5)P3 were separated by high-speed centrifugation 
(28 000 X g, 3 min at 4°C) in a refrigerated microfuge (Heraeus Sepa-
tech, Germany). Specifically bound [3H]Ins(l,4,5)P3 was routinely 
2500 dpm/assay, while non-specific binding (approx. 150-200 dpm/ 
assay) was defined by addition of 10 uM Ins(l,4,5)P3. Cerebellar 
membranes were selected for binding studies, because they exhibit 
an exceptionally high density population of essentially homotetramer-
ic type 1 Ins(l,4,5)P3R [22], 
2.4. Ca2+-mobilisation assay 
45Ca2+ mobilisation was assessed in saponin-permeabilized SH-
SY5Y cells at 20-22°C as previously described for SH-SY5Y cells 
[17] with each experiment performed in duplicate. Cells were used at 
a final concentration of 0.5-0.6 mg/ml of protein in a cytosolic-
like buffer consisting of KC1, 120 mM; KH 2P0 4 , 2 mM; 
(CH2COONa)2-6H20, 5 mM; MgCl2-6H20, 2.4 mM; Na2ATP, 
2 mM and HEPES free acid adjusted to pH 7.2 with 20% (w/v) 
KOH. In each assay ionomycin (5 uM, free acid, Calbiochem, UK) 
was used to define the total releasable 45Ca2+ pool and Ins(l,4,5)P3 
(20-30 uM) to define the Ins(l,4,5)P3-sensitive
 45Ca2+ pool. 
2.5. Data analysis 
EC50 and IC50 values (concentrations producing half-maximal stim-
ulation and inhibition, respectively) and slope factors were estimated 
by computer-assisted curve fitting using Prism version 2.0 (GraphPad 
Software, USA). Combined data from the independent experiments 
were expressed as means ±S.E.M., where » = 4-8. Statistical compar-
ison of the logio[IC5o] and logio[EC5o] was performed in Excel (Micro-
soft, UK), using unpaired Student's Mests (assuming unequal varian-
ces) at the p £ 0.05 level. 
3. Results 
3.1. Recognition by the Ins( 1,4,5 ) P^-receptor 
Ins(l ,4,5)P3 displaced [
3H]Ins(l,4,5)P3 from the 
Ins(l ,4,5)P3 -binding sites of pig cerebellar membranes produc-
ing a monophasic profile with an IC 5 0 of 11 n M (Table 1, Fig. 
2). 3F-Ins(l ,5)P2-4PS, 3F-Ins(l ,4)P2-5PS and 3F-Ins( l)P-
(4,5)PS2 also completely displaced specifically bound 
[3H]Ins(l,4,5)P3 from a single population of binding sites 
with respective IC50 values of 25.8, 80 and 109 n M (Table 
1, Fig. 2). 3F-Ins(l ,5)P2-4PS was only a 2.5-fold less potent 
ligand than Ins(l ,4,5)P3 , and significantly more potent than 
Table 1 
Interaction of Ins(l,4,5)P3 3F-Ins(l,5)P2-4PS, 3F-Ins(l,4)P2-5PS and 3F-Ins(l)P-(4,5)PS2 with the pig cerebellar Ins(l,4,5)P3R binding sites and 
the Ca2+ mobilising Ins(l,4,5)P3R of SH-SY5Y neuroblastoma cells 
(i) Ins(l,4,5)P3 binding (ii)
 45Ca2+ release: Ratio 
EC50/IC50 
Mean log(IC50)±S.E.M.; (IC50 nM) Mean log(EC50)±S.E.M.; (EC50 nM) 
Ins(l,4,5)P3 
3F-Ins(l,5)P2-4PS 
3F-Ins(l,4)P2-5PS 
3F-Ins(l)P-(4,5)PS2 
-7.955 ±0.046 (11) 
-7.577 ±0.019 (26) 
-7.097 ±0.006 (80) 
-6.962 ±0.017 (109) 
-7.003 ±0.019 (99) 
-6.373 ±0.075 (424) 
-5.446 ±0.041 (3579) 
-4.945 ±0.002 (11345) 
9 
16 
44.8 
104 
(i) Displacement of [3H]Ins(l,4,5)P3 from pig cerebellar Ins(l,4,5)P3 binding sites (n > 3) by Ins(l,4,5)P3, 3F-Ins(l,5)P2-4PS, 3F-Ins(l,4)P2-5PS and 
3F-Ins(l)P-(4,5)PS2. Ins(l,4,5)P3 and all the analogues completely displaced [
3H]Ins(l,4,5)P3 from an Ins(l,4,5)P3 binding site. Results are ex-
pressed as mean log(IC5o)±S.E.M.; the arithmetic means (nM) are indicated in parentheses. 
(ii) The 45Ca2+ mobilisation from SH-SY5Y human neuroblastoma cells (n>4) induced by Ins(l,4,5)P3, 3F-Ins(l,5)P2-4PS, 3F-Ins(l,4)P2-5PS and 
3F-Ins(l)P-(4,5)PS2. 3F-Ins(l,4)P2-5PS and 3F-Ins(l,5)P2-4PS were apparent full agonists mobilising the entire Ins(l,4,5)P3-sensitive Ca
2+ pool. 
3F-Ins(l)P-(4,5)PS2 was a partial agonist with maximally effective concentrations mobilising 64.3 ± 1.9% of the Ins(l,4,5)P3-sensitive Ca
2+ pool, 
respectively. The maximal effective concentrations were used for calculation of log(ECso)±S.E.M.; the arithmetic means (nM) are indicated in 
parentheses. See Section 2 for a complete description of the method. 
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both 3F-Ins(l,4)P2-5PS and 3F-Ins(l)P-(4,5)PS2, indicating 
that phosphorothioate modification of the 5-position produ-
ces significant perturbation of receptor affinity. 
3.2. i5Ca2+ release from saponin-permeabilised SH-SY5Y 
neuroblastoma cells 
Ins(l,4,5)P3 potently mobilised 72.3 ± 0.4% of the total pre-
loaded 45Ca2+ from SH-SY5Y cells, with an EC50 value of 99 
nM (Table 1; Fig. 3). 3F-Ins(l,5)P2-4PS (EC50 of 424 nM) 
and 3F-Ins(l,4)P2-5PS (EC50 = 3.6 uM) were both relatively 
weak full agonists for Ca2+ release in SH-SY5Y cells releasing 
Ca2+, exhibiting respectively 4- and 36-fold lower potency 
than Ins(l,4,5)P3, a clear demonstration that the 5-position, 
compared to 4-position, phosphorothioate substitution pro-
duced a more significant perturbation of Ca2+ mobilising effi-
ciency. Furthermore, 3F-Ins(l)P-(4,5)PS2 was an Ins-
(1,4,5)P3R partial agonist releasing only 64.3 ±1.9% of the 
Ins(l,4,5)P3-sensitive Ca
2+ pool, with an EC50 of 11.4 u.M. 
Indeed, we have also demonstrated that a maximally effective 
concentration of 3F-Ins(l)P-(4,5)PS2 (100 uM) was able to 
partially antagonise Ca2+ mobilisation by sub-optimal con-
centrations of Ins(l,4,5)P3. This inhibition was truly compet-
itive since it could readily br reversed in a concentration-de-
pendent fashion by using increasing doses of Ins(l,4,5)P3 to 
displace the 3F-Ins(l)P-(4,5)PS2 from the Ins(l,4,5)P3R (Fig. 
4). 
4. Discussion 
The interaction of Ins(l,4,5)P3 with its receptor is highly 
stereospecific, the presence of the vicinal 4,5-bisphosphates 
and the 6-hydroxyl being the crucial structural motif [2]. How-
ever, recent evidence obtained via structure-activity modelling 
of the very potent Ins(l,4,5)P3R agonists adenophostins A 
and B [24] and an adenophostin analogue [25] suggests that 
the 1-phosphate of Ins(l,4,5)P3 significantly enhances receptor 
binding affinity and efficacy. Phosphorothioate substitution is 
apparently well tolerated with »jyo-inositol 1,4,5-trisphos-
phorothioate [Ins(l,4,5)PS3] exhibiting only slightly lower af-
finity than Ins(l,4,5)P3 at binding sites characterised with 
[3H]Ins(l,4,5)P3. However, while phosphorothioate groups 
have a molecular volume only slightly greater than that of a 
phosphate group [14] they exhibit a distinctive chemistry. The 
replacement of oxygen with sulfur to form the phosphoro-
thioate group results in considerable disturbance in charge 
distribution with an increased negative charge on the sulfur 
and reduced negative charge on the remaining oxygens [26, 
27]. Indeed, Challiss et al. [6] recently demonstrated that 
OH OH 
OH OH / 3 / 
I / ^JL / OH 
OH 
Fig. 1. The structures of Ins(l,4,5)P3, 3F-Ins(l,5)P2-4PS, 3F-
Ins(l,4)P2-5PS and 3F-Ins(l)P-(4,5)PS2. 
Ins(l,4,5)P3: X = OH Y = 0 Z = 0 
3F-Ins(l,5)P2-4PS: X = F Y = S Z = 0 
3F-Ins(l,4)P2-5PS: X = F Y = 0 Z = S 
3F-Ins(l)P-(4,5)PS2: X = F Y=S Z = S. 
243 
-Í5 So Í 5 * 0 ^ 5 So Í 5 S -5.5 -5.0 3.5 
Log] o [concentration (M)] 
Fig. 2. Percentage displacement of specific [3H]Ins(l,4,5)P3 binding 
from pig cerebellar membrane Ins(l,4,5)P3 binding sites by 
Ins(l,4,5)P3 (■), 3F-Ins(l,5)P2-4PS ( A ) , 3F-Ins(l,4)P2-5PS (▼) and 
3F-Ins(l)P-(4,5)PS2 (•). Results are shown as mean ± standard error 
of n = 4 experiments. Non-specific binding was defined using 10 uM 
Ins(l,4,5)P3 (100% displacement); see Section 2 for further details. 
Ins(l,4,5)PS3 interacts with equal affinity at two sites in rat 
cerebellar membranes one of which is the Ins(l,4,5)P3R and 
the other a site which displays low affinity for Ins(l,4,5)P3. 
These changes in charge distribution appear to subtly affect 
interactions with the Ins(l,4,5)P3R binding pocket and there-
fore it is significant that many of the Ins(l,4,5)P3R partial 
agonists so far identified contain the 1,4,5-trisphosphoro-
thioate motif [11,16]. Indeed, it is significant that the only 
competitive antagonists of cAMP, that have so far been iden-
tified, are derived via phosphorothioate substitution [28,29]. 
The naturally occurring myo-inositol 1,3,4,6-tetrakisphos-
phate [Ins(l,3,4,6)P4] was the first partial agonist identified 
at the Ins(l,4,5)P3R [11,15]. Significantly, Ins(l,3,4,6)P4 
adopts a binding conformation which efficiently mimics 
Ins(l,4,5)P3 with the exception of presenting an axial (pseudo) 
3-phosphate [7]. However, L-cA/ro-inositol 2,3,5-trisphosphate 
[L-cA-Ins(2,3,5)P3], which binds in a similar orientation to 
Ins(l,3,4,6)P4, but presents an axial (pseudo) 3-position hy-
droxyl, was a full agonist [12], and indeed Ins(l,3,4,6)P4 was 
an apparent full agonist in some cell types [11]. A well recog-
nized approach for probing the interaction of an OH-group 
with a receptor protein involves replacement with fluorine 
[30]. The size and electronegativity of a fluorine substituent 
lies between those of a hydrogen and a hydroxy group, the C-
F and C-OH bonds have similar lengths and polarization, but 
a fluorine substituent can only accept and not donate hydro-
gen bonds [31]. 3-Fluoro-wiyo-inositol 1,4,5-trisphosphate [3F-
Ins(l,4,5)P3] is also among the most potent agonists identified 
at the Ins(l,4,5)P3 receptor, being only 2-3-fold less potent 
than Ins(l,4,5)P3, while being intrinsically resistant to 
Ins(l,4,5)P3-3-kinase activity [12,32,33]. 
We had previously hypothesised that phosphorothioate 
substitution of Ins(l,4,5)P3 accompanied by an additional 
structural perturbation on the inositol ring might produce 
partial agonism at the Ins(l,4,5)P3R [11]. Here we sought to 
test this hypothesis by rational design and synthesis of three 
analogues; 3F-Ins(l,5)P2-4PS, 3F-Ins(l,4)P2-5PS and 3F-
Ins(l)P-(4,5)PS2. Using these we hoped to define the impor-
tance of phosphorothioate substitution at the crucial vicinal 
4,5-bisphosphate motif, and since many of the partial agonists 
so far identified possessed a structural perturbation at the 3-
(or pseudo 3-) position [11,16,34] we decided to substitute the 
native 3-hydroxyl with a fluorine group in the hope of intro-
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ducing a minimal structural perturbation, which could never-
theless induce a loss in intrinsic activity. The native 1-phos-
phate group was maintained since although not crucial it does 
appear to significantly enhance the receptor interaction 
[24,25]. 
Ins(l,4,5)P3 binding studies revealed that all of the ana-
logues were able to monophasically fully displace 
[3H]Ins(l,4,5)P3 pig cerebellar Ins(l,4,5)P3R, with the follow-
ing order of affinity Ins(l,4,5)P3 > 3F-Ins(l,5)P2-4PS»3F-
Ins(l,4)P2-5PS>3F-Ins(l)P-(4,5)PS2. 3F-Ins(l,4)P2-5PS and 
3F-Ins(l)P-(4,5)PS2. Thus, interaction with the Ins(l,4,5)P3R 
was much more significantly perturbed by 5-phosphorothioate 
(PS) substitution compared to 4-PS substitution. Significantly 
this is the first evidence that the 5-position phosphate group is 
the dominant partner, within the 4,5-bisphosphate moiety that 
is so crucial for functional interaction with the Ins(l,4,5)P3R. 
Ca2+-mobilisation studies in permeabilized SH-SY5Y cells 
revealed a broadly similar trend with respective potencies of 
Ins(l,4,5)P3 > 3F-Ins(l,5)P2-4PS » 3F-Ins(l,4)P2-5PS » 3F-
Ins(l)P-(4,5)PS2. Among the analogues 3F-Ins(l)P-(4,5)PS2 
with its vicinal 4,5-bisphosphorothioate substitution was the 
only apparent partial agonist, mobilising just 64% of the in-
tracellular Ins(l,4,5)P3-sensitive Ca
2+ pool. We confirmed the 
dual partial agonist/antagonist nature of 3F-Ins(l)P-(4,5)PS2 
by demonstrating that at a maximally effective concentrations 
it was able to partially inhibit the Ca2+ mobilising activity of 
the full agonist Ins(l,4,5)P3 and that this inhibition could 
be overcome by competition with increasing concentra-
tions of Ins(l,4,5)P3 (Fig. 4). All the previously identified 
Ins(l,4,5)P3R partial agonists exhibited binding affinities 
weaker than Ins(l,4,5)P3 by some 2 orders of magnitude or 
greater [11,16]. In contrast, the affinity 3F-Ins(l)P-(4,5)PS2 for 
cerebellar Ins(l,4,5)P3R was only 10-fold weaker than 
Ins(l,4,5)P3 (Table 1). However, in contrast to the 1,4,5-tris-
phosphorothioate based partial agonists, 3F-Ins(l)P-(4,5)PS2 
retains the 1-position phosphate, which recent evidence sug-
gests significantly stabilizes and enhances interaction with the 
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Fig. 3. Intracellular Ca2+ mobilisation induced in permeabilized SH-
SY5Y cells by Ins(l,4,5)P3 (■), 3F-Ins(l,5)P2-4PS ( A ) , 3F-
Ins(l,4)P2-5PS ( T ) and 3F-Ins(l)P-(4,5)PS2 (•). Data indicate the 
percentage of 45Ca2+ released at 20-22°C from the intracellular 
Ins(l,4,5)P3-sensitive Ca
2+ stores of saponin permeabilised SH-
SY5Y neuroblastoma cells in the presence of increasing concentra-
tions of each compound. Results are shown as mean ± standard er-
ror of n = 4—8 experiments. Maximal Ca2+ release from intracellular 
Ins(l,4,5)P3-sensitive Ca
2+ stores was defined using an internal 
standard of 20-30 uM Ins(l,4,5)P3 (100% release); see Section 2 for 
a complete description of the method. 
Fig. 4. Effect of increasing concentration of Ins(l,4,5)P3 on maxi-
mally effective concentration of the partial agonist 3F-Ins(l)P-
(4,5)PS2. A maximally effective concentration of 3F-Ins(l)P-(4,5)PS2 
(100 uM), was found to significantly inhibit the ability of sub-maxi-
mal concentrations of Ins(l,4,5)P3 (0.3, 1 and 3 uM) to mobilise 
45Ca2+. However, this inhibition could be readily overcome by in-
creasing the concentration of Ins(l,4,5)P3 (10 and 30 uM). 
Ins(l,4,5)P3 (0.3 to 30 uM) plus control water vehicle are denoted 
by the black bars, while Ins(l,4,5)P3 (0 to 30 uM) plus maximally 
effective concentration of 3F-Ins(l)P-(4,5)PS2 (100 uM) are denoted 
by the grey bars. Statistical comparisons were performed with Excel 
(Microsoft, UK), using unpaired Student's ¿-tests (assuming unequal 
variances) statistical significance is indicated by * or ** which repre-
sent the p£, 0.05 and /?=s 0.01 levels, respectively. 
Ins(l,4,5)P3R binding site [24,25]. As for the receptor binding 
studies the 5-phosphorothioate (PS) substitution produced a 
much more significant perturbation of Ca2+ mobilising effi-
ciency. However, crucially double 4,5-bisphosphothioate sub-
stitution was require to trigger partial agonism for Ca2+ re-
lease at the Ins(l,4,5)P3R. 
When ratios of Ca2+ releasing potency (EC50) to binding 
affinity (IC50) were compared for Ins(l,4,5)P3 and the three 
analogues, the ratio exhibited a marked increase with the fol-
lowing rank order Ins(l,4,5)P3 > 3F-Ins(l,5)P2-4PS»3F-
Ins(l,4)P2-5PS»3F-Ins(l)P-(4,5)PS2 (Table 1). In this study 
since both the SH-SY5Y cells and cerebellar membranes ex-
press an essentially pure type 1 Ins(l,4,5)P3R population, this 
ratio gives an valid estimate of the ability of receptor binding 
site interaction to subsequently induce the conformation 
change required to open the type 1 Ins(l,4,5)P3R channel. 
Clearly Ins(l,4,5)P3 once bound was approx. 10-fold more 
efficient at producing Ca2+ mobilisation than 3F-Ins(l)P-
(4,5)PS2. Therefore, although 3F-Ins(l)P-(4,5)PS2 interacts 
relatively effectively with the ligand binding pocket of the 
receptor, presumably this interaction must be subtly different 
from that achieved by Ins(l,4,5)P3, because the interaction of 
3F-Ins(l)P-(4,5)PS2 fails to induces full Ins(l,4,5)P3R channel 
conductance at its maximally effective concentration. Indeed, 
both full agonists, 3F-Ins(l,5)P2-4PS, and in particular 3F-
Ins(l,4)P2-5PS, exhibit progressively higher EC50/IC50 ratios 
compared to Ins(l,4,5)P3. Therefore, perhaps they also induce 
sub-optimal conformational change of the Ins(l,4,5)P3R, 
which nevertheless generates a conductance state sufficiently 
efficient to allow full mobilisation of the Ins(l,4,5)P3-sensitive 
Ca2+ stores. 
Thus, the partial agonist 3F-Ins(l)P-(4,5)PS2 has defined 
some of the crucial structural features that can lead to loss 
of intrinsic activity at the Ins(l,4,5)P3R and therefore may be 
KA. Wilcox et allFEBS Letters 402 (1997) 241-245 245 
an important lead compound for the rational design of low 
intrinsic activity partial agonists and Ins(l ,4,5)P3R antago-
nists. 
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